Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: A systematic review

American Journal of Emergency Medicine

Volumn 33, Issue 2, 2015, Pages 133-141

  Alexander, Pauline ^a,d   Alkhawam, Lora ^b   Curry, Jason ^a   Levy, Phillip ^c   Pang, Peter S ^b   Storrow, Alan B ^a   Collins, Sean P ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CLEVIDIPINE; ENALAPRILAT; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NESIRITIDE; NITROPRUSSIDE SODIUM; RELAXIN; VASODILATOR AGENT;

ACUTE HEART FAILURE; ARTERIAL PRESSURE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BREATHING RATE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ELEVATED BLOOD PRESSURE; EMERGENCY WARD; HEART RATE; HEMODYNAMICS; HUMAN; HYPOTENSION; HYPOXEMIA; LUNG EDEMA; MEAN ARTERIAL PRESSURE; OXYGEN SATURATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ACUTE DISEASE; EMERGENCY HEALTH SERVICE; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION;

ACUTE DISEASE; EMERGENCY SERVICE, HOSPITAL; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84924761429     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2014.09.009     Document Type: Article

References (57)

1. S.P. Collins, P.S. Pang, and C.J. Lindsell et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes Eur J Heart Fail 12 11 2010 1253 1260
2. G.M. Felker, K.L. Lee, and D.A. Bull et al. Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 9 2011 797 805
3. N.L. Weintraub, S.P. Collins, and P.S. Pang et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association Circulation 122 19 2010 1975 1996
4. P. Levy, S. Compton, and R. Welch et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis Ann Emerg Med 50 2 2007 144 152
5. J.R. Teerlink, G. Cotter, and B.A. Davison et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial Lancet 381 9860 2013 29 39
6. G. Cotter, E. Metzkor, and E. Kaluski et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema Lancet 351 9100 1998 389 393
7. C.W. Yancy, M. Jessup, and B. Bozkurt et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 16 2013 e147 e239
8. A.S. Go, D. Mozaffarian, and V.L. Roger et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association Circulation 127 1 2013 e6 e245
9. A.B. Storrow, C.A. Jenkins, and W.H. Self et al. The burden of acute heart failure on US emergency departments JACC Heart Fail 2 3 2014 269 277
10. D. Moher, A. Liberati, and J. Tetzlaff et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 4 2009 264 269
11. A. Lundh, and P.C. Gotzsche Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies BMC Med Res Methodol 8 2008 22 30
12. K. Eastwood, A. Morgans, and K. Smith et al. Secondary triage in prehospital emergency ambulance services: a systematic review Emerg Med J 2014 10.1136/emermed-2013-203120 [Epub ahead of print]
13. N.R. Hoot, and D. Aronsky Systematic review of emergency department crowding: causes, effects, and solutions Ann Emerg Med 52 2 2008 126 136
14. J.F. Beltrame, C.J. Zeitz, and S.A. Unger et al. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema J Card Fail 4 4 1998 271 279
15. E.F. Aziz, M. Kukin, and F. Javed et al. Effect of adding nitroglycerin to early diuretic therapy on the morbidity and mortality of patients with chronic kidney disease presenting with acute decompensated heart failure Hosp Pract (Minneap) 39 1 2011 126 132
16. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial JAMA 287 12 2002 1531 1540
17. U. Elkayam, M.W. Akhter, and H. Singh et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure Am J Cardiol 93 2 2004 237 240
18. Y. Freund, S. Delerme, and J. Boddaert et al. Isosorbide dinitrate bolus for heart failure in elderly emergency patients: a retrospective study Eur J Emerg Med 18 5 2011 272 275
19. C. Harf, and R. Welter Emergency treatment of severe cardiogenic pulmonary edema with intravenous isosorbide-5-mononitrate Am J Cardiol 61 9 1988 22E 27E
20. W.S. Colucci, U. Elkayam, and D.P. Horton et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group N Engl J Med 343 4 2000 246 253
21. A.J. Burger, U. Elkayam, and M.T. Neibaur et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy Am J Cardiol 88 1 2001 35 39
22. A.J. Burger, D.P. Horton, and T. LeJemtel et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study Am Heart J 144 6 2002 1102 1108
23. S.L. Chow, S.A. O'Barr, and J. Peng et al. Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure J Card Fail 17 3 2011 181 187
24. R.L. Fitzgerald, R. Cremo, and N. Gardetto et al. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure Am Heart J 150 3 2005 471 477
25. W.L. Miller, K.A. Hartman, and M.F. Burritt et al. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure Clin Chem 51 3 2005 569 577
26. S. Fu, S. Yi, and B. Zhu et al. Efficacy and safety of a modified dosage regimen of nesiritide in patients older than 75 years with acute heart failure Aging Clin Exp Res 24 5 2012 524 529
27. J.F. Styron, P. Jois-Bilowich, and T. Tallman et al. Outcomes associated with nesiritide administration for acute decompensated heart failure in the emergency department observation unit: a single center experience Congest Heart Fail 15 3 2009 103 107
28. C.M. O'Connor, R.C. Starling, and A.F. Hernandez et al. Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 1 2011 32 43
29. T.L. Lenz, P.A. Foral, and M.A. Malesker et al. Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure Pharmacotherapy 24 9 2004 1137 1146
30. WFt Peacock, R. Holland, and R. Gyarmathy et al. Observation unit treatment of heart failure with nesiritide: results from the proaction trial J Emerg Med 29 3 2005 243 252
31. A.H. Miller, S. Nazeer, and P. Pepe et al. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment Ann Emerg Med 51 5 2008 571 578
32. D.A. Lewis, N.R. Gurram, and W.T. Abraham et al. Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure Am J Health Syst Pharm 60 Suppl. 4 2003 S16 S20
33. C. Bartone, S. Saghir, and S.G. Menon et al. Comparison of ultrafiltration, nesiritide, and usual care in acute decompensated heart failure Congest Heart Fail 14 6 2008 298 301
34. M.A. Silver, D.P. Horton, and J.K. Ghali et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure J Am Coll Cardiol 39 5 2002 798 803
35. J.D. Sackner-Bernstein, M. Kowalski, and M. Fox et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials JAMA 293 15 2005 1900 1905
36. J.D. Sackner-Bernstein, H.A. Skopicki, and K.D. Aaronson Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 12 2005 1487 1491
37. T.E. Owan, H.H. Chen, and R.P. Frantz et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction J Card Fail 14 4 2008 267 275
38. A. Sakr, P. Hahn, and T. Donohue et al. Nesiritide in the initial management of acute decompensated congestive heart failure Conn Med 72 9 2008 517 523
39. D.J. Wang, T.C. Dowling, and D. Meadows et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine Circulation 110 12 2004 1620 1625
40. R.M. Witteles, D. Kao, and D. Christopherson et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial J Am Coll Cardiol 50 19 2007 1835 1840
41. S. Arora, K. Clarke, and V. Srinivasan et al. Effect of nesiritide on renal function in patients admitted for decompensated heart failure QJM 100 11 2007 699 706
42. T. De Marco, P.A. Daly, and M. Liu et al. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure J Am Coll Cardiol 9 5 1987 1131 1138
43. D. Annane, E. Bellissant, and E. Pussard et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema Circulation 94 6 1996 1316 1324
44. M.M. Hirschl, M. Binder, and A. Bur et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises Arch Intern Med 155 20 1995 2217 2223
45. G.I. Nelson, S.P. Verma, and M. Hussain et al. A randomised study of the haemodynamic changes induced by venodilatation and arteriolar dilatation singly and together in left ventricular failure complicating acute myocardial infarction J Cardiovasc Pharmacol 6 2 1984 331 338
46. University Hospital B Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation study (GALACTIC) [cited 2013 August 4] Available from: http://clinicaltrials.gov/ct2/show/record/NCT00512759?term=heart+failure+AND+nitroglycerin&rank=3
47. T. Dschietzig, S. Teichman, and E. Unemori et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial J Card Fail 15 3 2009 182 190
48. P. Ponikowski, V. Mitrovic, and M. Ruda et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure Eur Heart J 35 7 2014 431 441
49. J.R. Teerlink, M. Metra, and G.M. Felker et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study Lancet 373 9673 2009 1429 1439
50. M. Metra, G. Cotter, and B.A. Davison et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes J Am Coll Cardiol 61 2 2013 196 206
51. Clinicaltrials.gov. Efficacy, safety and tolerability of serelaxin when added to standard therapy in AHF 2014 [cited 2014] Available from: http://clinicaltrials.gov/ct2/show/NCT01870778?term=NCT01870778
52. Ft Peacock, J. Varon, and R. Ebrahimi et al. Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis Congest Heart Fail 16 2 2010 55 59
53. J.R. Teerlink Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure Am Heart J 145 2 Suppl. 2003 S26 S33
54. W.F. Peacock, A. Chandra, and D. Char et al. Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO) Am Heart J 167 4 2014 529 536
55. M.D. Carlson, and P.M. Eckman Review of vasodilators in acute decompensated heart failure: the old and the new J Card Fail 19 7 2013 478 493
56. P.S. Pang, J.G. Cleland, and J.R. Teerlink et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach Eur Heart J 29 6 2008 816 824
57. A. Mebazaa, P.S. Pang, and M. Tavares et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: The URGENT-dyspnoea study Eur Heart J 31 7 2010 832 841